| Company Name: |
BePharm Ltd |
| Tel: |
400-685-9117 |
| Email: |
market@bepharm.com |
1-Methyl-1H-1,2,3-triazole-4-carbaldehyde manufacturers
|
| | 1-Methyl-1H-1,2,3-triazole-4-carbaldehyde Basic information | | Application |
| Product Name: | 1-Methyl-1H-1,2,3-triazole-4-carbaldehyde | | Synonyms: | 1-Methyl-1H-1,2,3-triazole-4-carbaldehyde;1H-1,2,3-triazole-4-carboxaldehyde, 1-methyl-;1-methyltriazole-4-carbaldehyde;1-Methyl-1H-1,2,3-triazole-4-carboxaldehyde;1-Methyl-1H-1H-1,2,3-triazol-4-formaldehyde;1-methyl-1H-1H-1,2,3-triazazole-4-methylaldehyde | | CAS: | 16681-69-9 | | MF: | C4H5N3O | | MW: | 111.1 | | EINECS: | | | Product Categories: | Intermediates | | Mol File: | 16681-69-9.mol |  |
| | 1-Methyl-1H-1,2,3-triazole-4-carbaldehyde Chemical Properties |
| Melting point | 113-113.5 °C | | Boiling point | 253.5±32.0 °C(Predicted) | | density | 1.31±0.1 g/cm3(Predicted) | | storage temp. | -20°C, sealed storage, away from moisture | | pka | -0.79±0.10(Predicted) | | Appearance | Light yellow to light brown Solid |
| | 1-Methyl-1H-1,2,3-triazole-4-carbaldehyde Usage And Synthesis |
| Application | 1-Methyl-1H-1H-1,2,3-triazol-4-carboxaldehyde can be used to prepare compounds with the following structure that can activate Nrf2. Activation of Nrf2 has been shown to have beneficial effects on both liver and kidney diseases. NAFLD (non-alcoholic fatty liver disease) is considered a leading cause of chronic liver disease worldwide. Other liver diseases (such as toxin-induced liver disease, viral hepatitis, and cirrhosis) may benefit from the treatment of Nrf2 activators. | | Synthesis Reference(s) | Journal of Heterocyclic Chemistry, 27, p. 2021, 1990 DOI: 10.1002/jhet.5570270733 |
| | 1-Methyl-1H-1,2,3-triazole-4-carbaldehyde Preparation Products And Raw materials |
|